autologous blood and marrow transplantation - Blog Science ...

Rodenhuis et al. 429
Figure 2. Progression-free survival of patients who responded to FE mC. The progression
free survival was calculated from the start of chemotherapy for all patients who had at least
50% regression of measurable or évaluable disease after the two courses ofFE mC, and who
were considered to have "chemosensitive disease. "
the progression-free survival data of this highly selected patient group are
immature. Nevertheless, some indication of the level of efficacy at this early time
can be obtained from Figs. 1 and 2. Not surprisingly, patients responding to two
courses of FEC with at least 50% regression of évaluable tumor appeared to have
a better prognosis than those who did not. The 2-year progression-free survival for
all patients was 22% (95% confidence interval[CI] 8^14%), and that for FECresponsive
patients was 47% (95% CI 20-66%).
Pharmacokinetic data
For two patients, the plasma concentration vs. time curves of carboplatin,
thiotepa, TEPA, cyclophosphamide, and 2-dechloroethyl cyclophosphamide are
shown in Fig. 3A-D. This information establishes the suitability of the methods to
obtain adequate curves in this patient group. Detailed analyses of more patients are
in progress and will be published elsewhere.
DISCUSSION
Three subsequent courses of tCTC could be administered to most patients in this
trial. As in the study with full-dose CTC, 7
end-organ toxicity such as hemorrhagic
cystitis and veno-occlusive disease occurred but were generally mild and did not